mercator | Micro Infusion Solutions

Six-month outcomes from phase-one trial of anti-inflammatory drug to assess benefit in acute DVT patients demonstrate ‘promise’

The open-label phase of the DEXTERITY-AFP trial investigating the Bullfrog microinfusion device—which involves the perivenous injection of the anti-inflammatory drug dexamethasone to improve patency and post-thrombotic syndrome (PTS) six months after thrombus removal...

Data from First Phase of DEXTERITY-AFP Study Unveiled at VEINS Meeting in Las Vegas

LAS VEGAS, NV / ACCESSWIRE / October 30, 2023 / The DEXTERITY-AFP study, led by vascular surgeon Dr. David Dexter and interventional radiologist Dr. Mahmood Razavi, reached a significant milestone with the release of data from its first phase during the Late Breaking...

Late-Breaking Clinical Trial Results Announced at The VEINS 2023

LAS VEGAS, Oct. 30, 2023 /PRNewswire/ — The VIVA Foundation, a not-for-profit organization dedicated to advancing the field of vascular medicine and intervention through education and research, announces the results for the Late-Breaking Clinical Trials session...

Mercator MedSystems Announces Publication of Results from TANGO Phase 2 Clinical Trial to Improve Outcomes after Below-Knee Arterial Revascularization

First U.S. Double-Blinded Randomized Controlled Trial to Date Addressing Unmet Needs in Critical Limb Ischemia SAN LEANDRO, CA / ACCESSWIRE / November 3, 2022 / Mercator MedSystems, Inc. (“Mercator”), a medical technology company specializing in local drug...

Mercator MedSystems Announces Receipt of NIH Grant for Research and Development of Local Anti-inflammatory Deep Vein Thrombosis Therapy

January 10, 2022, Emeryville, Calif. – Mercator MedSystems, Inc. (“Mercator” or the “company”), announced today that research has begun under a small business technology transfer (STTR) grant for approximately $300,000 funded by the National Institutes of...